The FDA last week approved
Roche's Evrysdi for the treatment of spinal muscular atrophy (SMA). Evrysdi
will be the third available treatment for the disorder, meaning Roche will face
off against Biogen's Spinraza and Novartis' Zolgensma for market share. For the
treatment of SMA under the pharmacy benefit, Spinraza currently has a slight
edge over Zolgensma, holding preferred status (with utilization management
restrictions) for 11% of all covered lives, compared to Zolgensma's 9%.
SOURCE: MMIT Analytics, as
of 8/10/20
No comments:
Post a Comment